Roche: another FDA breakthrough designation for Venclexta.
(CercleFinance.com) - The U.
S. Food and Drug Administration has granted breakthrough therapy designation for Venclexta for the treatment of acute myeloid leukemia (AML), an aggressive blood cancer.
The FDA granted the designation for Venclexta in combination with low-dose cytarabine for untreated patients who are ineligible for intensive chemotherapy.
This represents the second breakthrough therapy designation for Venclexta in acute myeloid leukemia, which can progress quickly if left untreated, and the fourth overall for the drug.
Venclexta is being developed by Roche subsidiary Genentech with US drugmaker AbbVie.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
S. Food and Drug Administration has granted breakthrough therapy designation for Venclexta for the treatment of acute myeloid leukemia (AML), an aggressive blood cancer.
The FDA granted the designation for Venclexta in combination with low-dose cytarabine for untreated patients who are ineligible for intensive chemotherapy.
This represents the second breakthrough therapy designation for Venclexta in acute myeloid leukemia, which can progress quickly if left untreated, and the fourth overall for the drug.
Venclexta is being developed by Roche subsidiary Genentech with US drugmaker AbbVie.
Copyright (c) 2017 CercleFinance.com. All rights reserved.